BioLineRx to Present at BIO CEO & Investor Conference 2008

JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX) announced today that Yuri Shoshan, Vice President of Finance and Corporate Development, will present a company overview and recently announced data from a phase 2a trial of BL-1020, a GABA-enhanced antipsychotic, at the BIO CEO & Investor Conference 2008 on Tuesday, February 12, 2008, at 10:15 AM ET at The Waldorf-Astoria Hotel in New York City.

A live webcast of the presentation may be accessed under the Events section of the Company's website, www.BioLineRx.com. A replay of the presentation will be available for 90 days following the presentation.

About BioLineRx

BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange (TASE:BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company’s leading programs are BL-1020, just completed Phase 2a and awaiting Phase 2b, for the treatment of schizophrenia, and BL-1040, which is about to initiate clinical trials, for the treatment of damaged heart tissue post-myocardial infarction. Additional products under development include compounds for the treatment of cancer and CNS, cardiovascular, metabolic, infectious and autoimmune diseases.

BioLineRx advances projects from early stage discovery and lead generation to advanced clinical trials. BioLineRx partners with researchers, universities and biotech companies to further the development of promising compounds. The Company was founded in 2003 by leaders in the Israeli life science arena including Teva Pharmaceuticals Ltd., venture capital firms Giza Venture Capital and Pitango Venture Capital, and Hadasit, the technology transfer company of Hadassah Hospital and the Jerusalem Development Authority. For more information, please visit www.biolinerx.com.